$FLNA

Filana Therapeutics won a vacatur of class certification in a securities suit by the Fifth Circuit, which found the Texas District Court misapplied legal standards. The case was remanded for further proceedings, with the appellate panel noting market inefficiency and meme-stock dynamics were not adequately considered. According to the Fifth Circuit, the district court did not properly evaluate evidence. Filana Therapeutics (FLNA) is the subject company.

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On October 16, 2026, the United States Court of Appeals for the Fifth Circuit (the “Fifth Circuit”) vacated the order of the U.S. District Court for the Western District of Texas (the “Texas District Court”) granting class certification in the securities

On October 1, 2026, significant insider trading activity was disclosed, including purchases by Hyperscale Data (GPUS) Executive Chairman Milton C. Ault III, Oracle (ORCL) director Stephen H. Rusckowski, and GameStop (GME) director Nat Turner. Notable sales included transactions by CoreWeave (CWV) CEO Michael N. Intrator, Workday (WDAY) director David A. Duffield, and Bumble (BMBL) 10% owner Blackstone. InvestingPro analysis suggests undervaluation for several of these companies.

Barry Richard (President & CEO) purchased 306,813 indirectly-held shares of FILANA THERAPEUTICS, INC. (FLNA) at an average of $0.91 ($0.90–$0.92, $0.28M total) across 2 trades over 2026-09-29 to 2026-09-30.

Barry Richard (President & CEO) purchased 93,091 indirectly-held shares of FILANA THERAPEUTICS, INC. (FLNA) at $0.84 on 2026-09-28.

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organizatio

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex_975585.htm EXHIBIT 10.1 ex_975585.htm Exhibit 10.1 FILANA THERAPEUTICS, INC. 2018 OMNIBUS INCENTIVE PLAN (CONFORMED COPY THROUGH AMENDMENT NO. 2) 1. Purposes of the Plan . The purposes of this Plan are to attract and retain the best available personnel, to provide ad